TERAPIA MEDICAMENTOSA NÃO-ESTEROIDE NO TRATAMENTO DA SÍNDROME DE CHURGSTRAUSS: UMA REVISÃO DE LITERATURA

• DOI: 10.22533/at.ed.94523181217

• Palavras-chave: Síndrome de Churg-Strauss; Tratamento da Síndrome de Churg-Strauss; Granulomatose Eosinofílica com Poliangeíte.

• Keywords: Churg-Strauss syndrome; Treatment of Churg-Strauss syndrome; Eosinophilic Granulomatosis with Polyangiits.

• Abstract: Churg-Strauss syndrome, also known as Eosinophilic Granulomatosis with Polyangiitis (GEPA), is a rare condition described as a generalized necrotizing vasculitis affecting small and medium-sized blood vessels, associated with eosinophilia and eventually asthma. In addition, the disease can affect the nervous, respiratory, cardiac, renal, lymphatic, and skin systems. This research aims to identify the most effective intervention in the further treatment of GEPA, aiming for the best clinical benefit, administration time and drug dose. This study was based on literature searches of articles published between the years 2012 and 2020, in databases such as PubMed, BVS and Cochrane. Sixteen articles were found where the sample, age range, treatment time, clinical benefit and remission rate of the studies are addressed. This study showed that in recent years the drugs chosen as favorites in the treatment of the disease were the biological immunosuppressants, however, the use of conventional immunosuppressants cannot be ruled out depending on the specificity of each case. Thus, we highlight Mepolizumab as the main agent capable of achieving clinical benefit, inducing remission and maintaining GEPA.